Allergan's Botox Off-Label Promotion Suit Raises Questions, But Why Would Wall Street Care?

Allergan's lawsuit against FDA over post-marketing safety restrictions for Botox is yet another new wrinkle that may help define the significance of the new "Safety First" regulatory era. But there is more to this case than meets the eye.